Actively Recruiting
Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
Led by Dr. med. Christian Rothermundt · Updated on 2026-01-13
6900
Participants Needed
1
Research Sites
1043 weeks
Total Duration
On this page
Sponsors
D
Dr. med. Christian Rothermundt
Lead Sponsor
G
German Testicular Cancer Study Group
Collaborating Sponsor
AI-Summary
What this Trial Is About
The majority of testicular cancer patients can be cured with cisplatin-based chemotherapy. Mortality has been reduced even more within the last 15 years due to the stringent application of standard chemotherapy followed by resection of residual disease. This is a positive development considering that testicular cancer usually affects young men. Active surveillance has become an acceptable and widely used strategy in stage I testicular cancer. Thus, it is important to follow these patients in a standardized way and to adhere to a rationale surveillance strategy. There is no international consensus regarding follow-up of testicular cancer patients. Stratification according to risks and patterns of relapse would allow to tailor follow-up schedules, aiming at early identification of relapse without causing unnecessary harm by using excessive radiation in these young long-term survivors. Follow-up procedures should not only aim at detecting relapse, but also long-term side effects from therapy, including hypogonadism, metabolic syndrome, cardiovascular disease and secondary malignancies. The Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS) will comprise consecutive newly diagnosed testicular cancer patients and is the first study to prospectively evaluate the initial indictor of relapse in testicular cancer patients, the frequency and pattern of relapse and document long-term toxicities of the treatment (cardiovascular, gonadal, hearing impairment, renal function and second malignancies) and psychosocial aspects. This cohort study will determine the relevance of each test performed routinely during follow-up. The collected data will have direct implications for the care of patients with testicular cancer and inform future adaptations of follow-up recommendations. The dataset will give information on baseline factors of testicular cancer patients patients, current treatment strategies in Switzerland, Austria and Germany, outcome and late sequelae.
CONDITIONS
Official Title
Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided written informed consent
- Diagnosed with seminoma or non-seminoma testicular cancer confirmed by tissue examination
- For seminoma: in complete remission or have lymph nodes smaller than 3 cm or PET negative partial remission
- For non-seminoma: in complete remission
- Completed treatment within the last 6 months
- Able and willing to attend regular surveillance appointments
You will not qualify if you...
- Having another cancer diagnosed within the last 5 years
- Unable to comply with trial tests or follow-up schedules for any reason
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kantonsspital St.Gallen; Onkologie/Haematologie
Sankt Gallen, Switzerland, 9007
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here